miRNAs associated with prostate cancer risk and progression

Authors

Hung N. Luu, Vanderbilt University
Hui-Yi Lin, Louisiana State University
Karina Dalsgaard Sorensen, Aarhus University
Olorunseun O. Ogunwobi, CUNY Hunter CollegeFollow
Nagi Kumar, H. Lee Moffitt Cancer Center and Research Institute
Ganna Chornokur, H. Lee Moffitt Cancer Center and Research Institute
Catherine Phelan, H. Lee Moffitt Cancer Center and Research Institute
Dominique Jones, University of Louisville
LaCreis Kidd, University of Louisville
Jyotsna Batra, Queensland University of Technology
Kosj Yamoah, H. Lee Moffitt Cancer Center and Research Institute
Anders Berglund, H. Lee Moffitt Cancer Center and Research Institute
Robert J. Rounbehler, H. Lee Moffitt Cancer Center and Research Institute
Mihi Yang, Sookmyoung Women’s University
Sang Haak Lee, The Catholic University of Korea
Nahyeon Kang, The Catholic University of Korea
Seung Joon Kim, The Catholic University of Korea
Jong Y. Park, H. Lee Moffitt Cancer Center and Research Institute
Giuliano Di Pietro, H. Lee Moffitt Cancer Center and Research Institute

Document Type

Article

Publication Date

3-20-2017

Abstract

Prostate cancer is the most common malignancy among men in the US. Though considerable improvement in the diagnosis of prostate cancer has been achieved in the past decade, predicting disease outcome remains a major clinical challenge. Recent expression profiling studies in prostate cancer suggest microRNAs (miRNAs) may serve as potential biomarkers for prostate cancer risk and disease progression. miRNAs comprise a large family of about 22-nucleotide-long non-protein coding RNAs, regulate gene expression post-transcriptionally and participate in the regulation of numerous cellular processes. In this review, we discuss the current status of miRNA in studies evaluating the disease progression of prostate cancer. The discussion highlights key findings from previous studies, which reported the role of miRNAs in risk and progression of prostate cancer, providing an understanding of the influence of miRNA on prostate cancer. Our review indicates that somewhat consistent results exist between these studies and reports on several prostate cancer related miRNAs. Present promising candidates are miR-1, −21, 106b, 141, −145, −205, −221, and −375, which are the most frequently studied and seem to be the most promising for diagnosis and prognosis for prostate cancer. Nevertheless, the findings from previous studies suggest miRNAs may play an important role in the risk and progression of prostate cancer as promising biomarkers.

Comments

This article was originally published in BMC Urology, available at DOI 10.1186/s12894-017-0206-6.

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).

The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.